Royal Bank Of Canada Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $30.00

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price objective decreased by research analysts at Royal Bank Of Canada from $31.00 to $30.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target points to a potential upside of 22.72% from the company’s previous close.

Several other research analysts have also commented on ACAD. JPMorgan Chase & Co. decreased their target price on ACADIA Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating for the company in a research report on Monday, November 17th. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price objective on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 3rd. Wall Street Zen lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Citizens Jmp raised their price target on shares of ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the stock a “market outperform” rating in a research report on Thursday. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $30.70.

ACADIA Pharmaceuticals Stock Down 2.1%

Shares of ACAD traded down $0.52 during midday trading on Thursday, hitting $24.45. The company had a trading volume of 825,306 shares, compared to its average volume of 1,400,171. The stock has a market cap of $4.14 billion, a price-to-earnings ratio of 15.77, a PEG ratio of 8.63 and a beta of 0.66. The company’s 50 day moving average price is $25.62 and its 200 day moving average price is $24.45. ACADIA Pharmaceuticals has a 52 week low of $13.40 and a 52 week high of $28.35.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $1.48. The business had revenue of $298.00 million during the quarter, compared to the consensus estimate of $292.54 million. ACADIA Pharmaceuticals had a return on equity of 14.61% and a net margin of 24.94%.The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period last year, the firm earned $0.86 earnings per share. Equities analysts anticipate that ACADIA Pharmaceuticals will post 0.7 EPS for the current fiscal year.

Insider Activity at ACADIA Pharmaceuticals

In related news, EVP Jennifer J. Rhodes sold 6,950 shares of ACADIA Pharmaceuticals stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $23.38, for a total transaction of $162,491.00. Following the sale, the executive vice president directly owned 7,609 shares in the company, valued at $177,898.42. The trade was a 47.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 26.50% of the company’s stock.

Institutional Trading of ACADIA Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ACAD. Royal Bank of Canada boosted its holdings in shares of ACADIA Pharmaceuticals by 74.4% in the first quarter. Royal Bank of Canada now owns 80,528 shares of the biopharmaceutical company’s stock valued at $1,338,000 after acquiring an additional 34,352 shares in the last quarter. AQR Capital Management LLC lifted its position in ACADIA Pharmaceuticals by 3.8% in the first quarter. AQR Capital Management LLC now owns 67,672 shares of the biopharmaceutical company’s stock worth $1,124,000 after purchasing an additional 2,492 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in ACADIA Pharmaceuticals by 7.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,952 shares of the biopharmaceutical company’s stock valued at $1,498,000 after purchasing an additional 6,303 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of ACADIA Pharmaceuticals during the 1st quarter valued at $186,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of ACADIA Pharmaceuticals by 14.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 251,056 shares of the biopharmaceutical company’s stock worth $4,170,000 after buying an additional 31,931 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors.

ACADIA Pharmaceuticals News Roundup

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Q4 results materially beat EPS expectations — reported $1.60 EPS vs. consensus ~$0.12 and roughly $298M in revenue (slight revenue beat) with YoY revenue growth and healthy margins; this is the main near-term catalyst. Read More.
• Positive Sentiment: Management set an ambitious FY‑2026 revenue target (up to about $1.28B) and highlighted continued commercialization of DAYBUE, STIX and NUPLAZID — signals of durable top-line growth if execution continues. Read More.
• Positive Sentiment: Analyst coverage turned bullish: Wolfe Research initiated with an “outperform” and a $33 price target, which reinforces upside expectations among institutional investors. Read More.
• Neutral Sentiment: Company published the full earnings release, slide deck and call transcript providing more color on commercial uptake and R&D priorities for investors to model future revenue and margin trends. Read More.
• Neutral Sentiment: Full Q4 earnings call transcript is available for deeper read of management’s commentary on DAYBUE prescriptions, NUPLAZID dynamics and pipeline timelines. Read More.
• Neutral Sentiment: Industry coverage/comparisons continue to surface (e.g., ACAD vs. Apellis) — useful for relative valuation context but not an immediate catalyst. Read More.
• Negative Sentiment: Policy/regulatory risk: mid‑size biotechs, including Acadia, face potential headwinds from proposals like MFN pricing pressure that could affect pricing and innovation economics if enacted. Read More.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.